AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

Labomar

Report Publication Announcement Nov 25, 2022

4144_rns_2022-11-25_5738fb95-7e59-4c45-b670-5222a10acf4f.pdf

Report Publication Announcement

Open in Viewer

Opens in native device viewer

Labomar is attending "Mid & Small in Milan" on November 30, 2022

Istrana (TV), November 25, 2022 — Labomar SpA (Ticker: LBM), an Italian-based international nutraceutical enterprise listed on the Euronext Growth Milan market, is attending the "Mid & Small in Milan", event organized by Virgilio IR, that will be held on November, 29 and 30, 2022 in Milan, at Piazza degli Affari.

On November 30, 2022, the Top Management of Labomar, will share with the financial community the latest company news and strategies' update.

Materials dedicated to investors are available on the Company's website www.labomar.com, "Investors" section.

*****

Labomar Profile

Founded by Walter Bertin in Istrana (province of Treviso) in 1998, Labomar is specialised in the development and production of food supplements, medical devices, foods for special medical purposes and cosmetics for third parties. Over more than 20 years, Labomar has built a business model which sets it apart from its competitors and generates value for all stakeholders, providing a comprehensive service and a high quality and productivity standard. The company boasts a well structured and cutting-edge research and development department with a particular focus on innovation, a commercial team which reacts quickly to market demands and a high level of product differentiation thanks to its proprietary patents and formulas.

Labomar reported in 2021 consolidated revenues of approx. Euro 65.4 million, up 7.1% on 2020. The 2021 figure includes, in addition to the revenues of the parent company and the Canadian Entreprises ImportFab Inc., also those for H2 of the Welcare Group and, for December alone, of Labiotre Srl. Labomar SpA's revenues in 2021 were approx. Euro 53.8 million, increasing nearly 4 percentage points on 2020.

Labomar in 2021 acquired 70% of the Welcare Group. The Group comprises Welcare Industries Spa and Welcare Research Srl, producers of medical devices for skincare, with its registered office in Orvieto. LaboVar Srl was also established - 51% owned by Labomar - for the sale of nutraceutical products on an e-commerce platform on the Chinese market. Labomar then acquired full control of Labiotre Srl, a Tuscan enterprise specialising in the production of plant extracts, fully integrating the supply chain concept advocated by the company.

Labomar sincerely believes in operating as a business centred on sustainability and the well-being of the individual, the environment and the community. It has therefore amended it By-Laws to become a Benefit company. This new legal status, introduced in Italy in 2016, formalises the decision to develop a responsible, sustainable and transparent development model, which marries operating-earnings objectives with social and environmental aspects.

For further information: Labomar Press Office Thanai Bernardini - +39.335.7245418 - [email protected] Alessandro Bozzi Valenti - +39.348.0090866 - [email protected]

Investor Relations Labomar Claudio De Nadai - +39.0422.677203 - [email protected] Mara Di Giorgio - +39 335 7737417 - [email protected]

Euronext Growth Advisor Banca Mediolanum - +39 02 9049 2525 - [email protected]

Talk to a Data Expert

Have a question? We'll get back to you promptly.